SCHEMBL2605154

SCHEMBL2605154

CCCCCCCCCCCCCC[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](N)CO[C@H]1OC(COCc2ccccc2)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SSTR1 P30872 4/20 0.43
▸ SSTR2 P30874 4/20 0.43
▸ SSTR4 P31391 4/20 0.43
▸ SSTR3 P32745 4/20 0.43
▸ SSTR5 P35346 4/20 0.43
▸ PTPN1 P18031 8/20 0.41
▸ CDC25B P30305 8/20 0.41
▸ PTPN2 P17706 4/20 0.40
▸ PTPN6 P29350 4/20 0.40
▸ PTPN11 Q06124 4/20 0.40
▸ SELP P16109 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ NT5E P21589 1/20 0.37
▸ ADRB2 P07550 1/20 0.37
▸ TACR1 P25103 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14477827 0.88 SELP (0.32) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL16980592 0.88 SELP (0.32) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL29827603 0.85 SSTR1 (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2605166 0.85 SELP (0.43) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2605158 0.83 SELP (0.41) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2605155 0.83 SELP (0.42) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2605161 0.81 SELP (0.40) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2605152 0.81 TNF (0.47) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL13377703 0.77 SSTR1 (0.44) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL22168445 0.76 SSTR1 (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163705-B2 Glycolipid and use thereof RIKEN (JP) 2012-04-24 — — US disclosed
US-20090221516-A1 NOVEL GLYCOLIPID AND USE THEREOF RIKEN (JP) 2009-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221516-A1 NOVEL GLYCOLIPID AND USE THEREOF IL4, IL2, IL5 SSTR1 1454/4885SSTR2 1511/4885SSTR4 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback